ERBB2 and Hodgkins lymphoma: As for the clinical study, a phase III EGF104900 trial demonstrated that lapatinib plus trastuzumab (HL) had a statistically significant advantage over the group on lapatinib monotherapy in PFS (P = .008, 95% CI, 0.57‐0.93).7 This study indicated that the dual anti‐Her2 treatment of HL was superior to lapatinib alone.